Insulin Caused Drug Resistance to Oxaliplatin in Colon Cancer Cell Line HT29

Overview

Journal J Gastrointest Oncol

Date 2012 Jul 20

PMID 22811824

Citations 29

Authors

Jiezhong Chen

Xu-Feng Huang

Liang Qiao

Andrew Katsifis

Affiliations

Soon will be listed here.

Abstract

Introduction: Obesity is associated with poor prognosis of colon cancer and the mechanism for this is unknown. This study tested insulin-caused resistance to oxaliplatin via activation of PI3K/Akt pathway in HT29 cells.

Methods: The effect of insulin on oxaliplatin cytotoxicity was tested by pre-incubation with 1µM insulin followed by addition of oxaliplatin. Phosphorylated Akt was determined by Western blotting.

Results: Addition of 1µM insulin decreased the cytotoxicity of oxaliplatin. PI3K specific inhibitor Ly294002 abolished such an effect of insulin. pAkt were highly activated by insulin plus oxaliplatin and inhibited by addition of Ly294002.

Conclusion: Insulin decreased drug efficacy of oxaliplatin in HT29 cells, which could be mediated by the activation of the PI3K/Akt pathway.

Citing Articles

Irregular delay of adjuvant chemotherapy correlated with poor outcome in stage II-III colorectal cancer.

Chen Y, Xu M, Ye Q, Xiang J, Xue T, Yang T BMC Cancer. 2022; 22(1):670.

PMID: 35715761 PMC: 9206266. DOI: 10.1186/s12885-022-09767-y.

MiR-221 Expression Level Correlates with Insulin-Induced Doxorubicin Resistance in MCF-7 Breast Cancer Cells.

Kheradmand P, Vallian Boroojeni S, Esmaeili-Mahani S Cell J. 2021; 23(3):329-334.

PMID: 34308576 PMC: 8286461. DOI: 10.22074/cellj.2021.7153.

SILAC-Based Quantitative Proteomic Analysis of Oxaliplatin-Resistant Pancreatic Cancer Cells.

Kim Y, Kim E, Song M, Kim T, Jang H, Kang D Cancers (Basel). 2021; 13(4).

PMID: 33578797 PMC: 7916634. DOI: 10.3390/cancers13040724.

Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance).

Brown J, Zhang S, Ou F, Venook A, Niedzwiecki D, Lenz H JNCI Cancer Spectr. 2020; 4(1):pkz078.

PMID: 32259016 PMC: 7043296. DOI: 10.1093/jncics/pkz078.

The emerging role of long non-coding RNAs in the drug resistance of colorectal cancer.

Chen D, Xu R Int J Clin Exp Pathol. 2020; 11(10):4735-4743.

PMID: 31949549 PMC: 6962903.

References

Ma , Giovannucci , Pollak , Stampfer . RESPONSE: Re: Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF-Binding Protein-3. J Natl Cancer Inst. 1999; 91(23):2052. DOI: 10.1093/jnci/91.23.2052. View

Gunter M, Hoover D, Yu H, Wassertheil-Smoller S, Rohan T, Manson J . Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res. 2008; 68(1):329-37. PMC: 4225702. DOI: 10.1158/0008-5472.CAN-07-2946. View

Rose D, Komninou D, Stephenson G . Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev. 2004; 5(3):153-65. DOI: 10.1111/j.1467-789X.2004.00142.x. View

Page C, Lin H, Jin Y, Castle V, Nunez G, Huang M . Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res. 2000; 20(1A):407-16. View

Hector S, ZDANOWICZ J, Hitt S, Pendyala L . In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol. 2002; 48(5):398-406. DOI: 10.1007/s002800100363. View

Calle E, Kaaks R . Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004; 4(8):579-91. DOI: 10.1038/nrc1408. View

Healy L, Ryan A, Sutton E, Younger K, Mehigan B, Stephens R . Impact of obesity on surgical and oncological outcomes in the management of colorectal cancer. Int J Colorectal Dis. 2010; 25(11):1293-9. DOI: 10.1007/s00384-010-0963-0. View

Brognard J, Clark A, Ni Y, Dennis P . Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001; 61(10):3986-97. View

Vie N, Copois V, Bascoul-Mollevi C, Denis V, Bec N, Robert B . Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells. Mol Cancer. 2008; 7:14. PMC: 2245978. DOI: 10.1186/1476-4598-7-14. View

10.

Goodwin P, Ligibel J, Stambolic V . Metformin in breast cancer: time for action. J Clin Oncol. 2009; 27(20):3271-3. DOI: 10.1200/JCO.2009.22.1630. View

11.

Giovannucci E, Pollak M, Platz E, Willett W, Stampfer M, Majeed N . A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev. 2000; 9(4):345-9. View

12.

Adlard J, Richman S, Seymour M, Quirke P . Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol. 2002; 3(2):75-82. DOI: 10.1016/s1470-2045(02)00648-4. View

13.

Iwatsuki M, Mimori K, Yokobori T, Tanaka F, Tahara K, Inoue H . A platinum agent resistance gene, POLB, is a prognostic indicator in colorectal cancer. J Surg Oncol. 2009; 100(3):261-6. DOI: 10.1002/jso.21275. View

14.

Chen J . Is Src the key to understanding metastasis and developing new treatments for colon cancer?. Nat Clin Pract Gastroenterol Hepatol. 2008; 5(6):306-7. DOI: 10.1038/ncpgasthep1141. View

15.

Plasencia C, Martinez-Balibrea E, Martinez-Cardus A, Quinn D, Abad A, Neamati N . Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells. Int J Oncol. 2006; 29(1):225-35. DOI: 10.3892/ijo.29.1.225. View

16.

Wei E, Ma J, Pollak M, Rifai N, Fuchs C, Hankinson S . A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev. 2005; 14(4):850-5. DOI: 10.1158/1055-9965.EPI-04-0661. View

17.

Huang X, Chen J . Obesity, the PI3K/Akt signal pathway and colon cancer. Obes Rev. 2009; 10(6):610-6. DOI: 10.1111/j.1467-789X.2009.00607.x. View

18.

Boyer J, Allen W, McLean E, Wilson P, McCulla A, Moore S . Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res. 2006; 66(5):2765-77. DOI: 10.1158/0008-5472.CAN-05-2693. View

19.

Ekblad L, Kjellstrom J, Johnsson A . Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells. Anticancer Drugs. 2010; 21(5):523-31. DOI: 10.1097/CAD.0b013e328337b867. View

20.

Pollak M . Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008; 8(12):915-28. DOI: 10.1038/nrc2536. View